KR101783383B1 - 알파-(1,2)-분지형 알파-(1,6) 올리고덱스트란을 제조하기 위한 조성물 및 방법 - Google Patents

알파-(1,2)-분지형 알파-(1,6) 올리고덱스트란을 제조하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR101783383B1
KR101783383B1 KR1020117029265A KR20117029265A KR101783383B1 KR 101783383 B1 KR101783383 B1 KR 101783383B1 KR 1020117029265 A KR1020117029265 A KR 1020117029265A KR 20117029265 A KR20117029265 A KR 20117029265A KR 101783383 B1 KR101783383 B1 KR 101783383B1
Authority
KR
South Korea
Prior art keywords
alpha
oligodextran
delete delete
composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117029265A
Other languages
English (en)
Korean (ko)
Other versions
KR20120027314A (ko
Inventor
티에리 나이예
알렉산드라 아이너핸드
미첼 로페즈
수잔 엠. 포터
마갈리 리마우드-시메온
피에르 프레데릭 엠마뉴엘 몽산
Original Assignee
테이트 ＆ 라일 인그레디언츠 프랑스 에스에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테이트 ＆ 라일 인그레디언츠 프랑스 에스에이에스 filed Critical 테이트 ＆ 라일 인그레디언츠 프랑스 에스에이에스
Publication of KR20120027314A publication Critical patent/KR20120027314A/ko
Application granted granted Critical
Publication of KR101783383B1 publication Critical patent/KR101783383B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C12P19/08—Dextran
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
    • C08L2205/025—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group containing two or more polymers of the same hierarchy C08L, and differing only in parameters such as density, comonomer content, molecular weight, structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
KR1020117029265A 2009-05-07 2010-05-07 알파-(1,2)-분지형 알파-(1,6) 올리고덱스트란을 제조하기 위한 조성물 및 방법 Active KR101783383B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17624209P 2009-05-07 2009-05-07
US61/176,242 2009-05-07
PCT/US2010/033984 WO2010129839A1 (en) 2009-05-07 2010-05-07 Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans

Publications (2)

Publication Number Publication Date
KR20120027314A KR20120027314A (ko) 2012-03-21
KR101783383B1 true KR101783383B1 (ko) 2017-09-29

Family

ID=42236313

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117029265A Active KR101783383B1 (ko) 2009-05-07 2010-05-07 알파-(1,2)-분지형 알파-(1,6) 올리고덱스트란을 제조하기 위한 조성물 및 방법

Country Status (11)

Country Link
US (3) US8816067B2 (https=)
EP (1) EP2427499A1 (https=)
JP (2) JP6077303B2 (https=)
KR (1) KR101783383B1 (https=)
CN (1) CN102439048B (https=)
AU (1) AU2010245761B2 (https=)
BR (1) BRPI1014800A8 (https=)
CA (1) CA2761150C (https=)
IL (1) IL215936A (https=)
MX (1) MX2011011659A (https=)
WO (1) WO2010129839A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240131494A (ko) 2023-02-23 2024-09-02 유선균 웨이셀라 시바리아 ysk01 균주 및 이의 용도

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1014800A8 (pt) 2009-05-07 2016-10-11 Tate & Lyle Ingredients France SAS "composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas"
AU2011293625B2 (en) * 2010-08-25 2015-09-24 Tate & Lyle Ingredients Americas Llc Synbiotic product
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
BR112014010660A2 (pt) * 2011-11-04 2017-05-09 Gen Mills Inc métodos e composições para modular bactéria gastrointestinal
WO2013130624A2 (en) * 2012-02-28 2013-09-06 Cornell University Probiotic compositions and methods
IN2014DN07752A (https=) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
KR101381794B1 (ko) * 2012-04-10 2014-04-07 씨제이제일제당 (주) 타가토스 및 프로바이오틱 유산균을 함유하는 신바이오틱 식품 조성물
WO2014007606A1 (en) * 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
US20150296851A1 (en) * 2012-11-27 2015-10-22 Shanghai Jiao Tong University Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof
US20150335615A1 (en) * 2013-01-04 2015-11-26 Toshihisa Kawai Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
AU2015223027B2 (en) * 2014-02-27 2018-09-20 Nutrition & Biosciences USA 4, Inc. Enzymatic hydrolysis of disaccharides and oligosaccharides using alpha-glucosidase enzymes
CA2949289A1 (en) * 2014-05-29 2015-12-03 E. I. Du Pont De Nemours And Company Enzymatic synthesis of soluble glucan fiber
US20170204442A1 (en) 2014-05-29 2017-07-20 E I Du Pont De Nemours And Company Enzymatic synthesis of soluble glucan fiber
BR112016027867A2 (pt) 2014-05-29 2017-10-24 Du Pont composições de fibra e de carboidrato, produto alimentício, métodos para produzir uma composição de fibra, de carboidrato, para reduzir o índice glicêmico e para inibir a elevação do nível de açúcar, composição cosmética, uso da composição de fibra e composição
BR112016027887A2 (pt) 2014-05-29 2017-10-24 Du Pont composições de fibra e de carboidrato, produto alimentício, métodos para produzir uma composição de fibra, para produzir uma composição de carboidratos misturada, método para reduzir o índice glicêmico, método para inibir a elevação do nível de açúcar no sangue, composição cosmética, uso da composição e composição
MX2016015703A (es) * 2014-05-29 2017-03-16 Du Pont Sintesis enzimatica de fibra de glucano soluble.
WO2015183722A1 (en) * 2014-05-29 2015-12-03 E. I. Du Pont De Nemours And Company Enzymatic synthesis of soluble glucan fiber
BR112017000345B1 (pt) 2014-07-09 2022-04-26 Cadena Bio, Inc Composições de oligossacarídeo, métodos para produção das mesmas e produto alimentar
FR3024158A1 (fr) * 2014-07-28 2016-01-29 Inst Nat Sciences Appliq Proteine a activite dextrane-saccharase et applications
US10702545B2 (en) * 2014-09-22 2020-07-07 Nihon Shokuhin Co., Ltd. Slowly digestible, sustained-type energy supplying agent
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
US20160165941A1 (en) * 2014-11-21 2016-06-16 Flipn'Sweet, LLC Sugar substitute compositions comprising digestion resistent soluble fiber
EP3237455B1 (en) 2014-12-22 2020-03-04 DuPont Industrial Biosciences USA, LLC Polysaccharide compositions for absorbing aqueous liquid
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
EP3862002A1 (en) 2015-01-26 2021-08-11 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
JP6722697B2 (ja) 2015-01-26 2020-07-15 カデナ・バイオ・インコーポレイテッド 動物飼料として使用するためのオリゴ糖組成物及びその生成方法
CN107771083A (zh) 2015-04-23 2018-03-06 卡莱多生物科技有限公司 聚糖治疗剂和治疗方法
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
ME03511B (me) 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
EP3371228B1 (en) * 2015-11-05 2022-08-31 Nutrition & Biosciences USA 4, Inc. Dextran-poly alpha-1,3-glucan graft copolymers and synthesis methods thereof
WO2017083228A1 (en) 2015-11-13 2017-05-18 E. I. Du Pont De Nemours And Company Glucan fiber compositions for use in laundry care and fabric care
WO2017083229A1 (en) 2015-11-13 2017-05-18 E. I. Du Pont De Nemours And Company Glucan fiber compositions for use in laundry care and fabric care
EP3374488B1 (en) 2015-11-13 2020-10-14 DuPont Industrial Biosciences USA, LLC Glucan fiber compositions for use in laundry care and fabric care
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP7064435B2 (ja) 2015-11-26 2022-05-10 ニュートリション・アンド・バイオサイエンシーズ・ユーエスエー・フォー，インコーポレイテッド α－１，２－分岐鎖を有するグルカンを生成することができるポリペプチドおよびその使用
ES3016735T3 (en) 2016-01-18 2025-05-09 Isothrive Inc Maltosyl-isomaltooligosaccharides
JP6785509B2 (ja) * 2016-02-24 2020-11-18 Ｎｏｓｔｅｒ株式会社 ロイコノストック メセンテロイデスが産生する菌体外多糖を有効成分として含む代謝異常の予防または治療用組成物
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
JP2020513410A (ja) * 2016-12-06 2020-05-14 カレイド・バイオサイエンシズ・インコーポレイテッド グリカンポリマーおよびその関連方法
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
ES2877726T3 (es) 2017-05-22 2021-11-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
EP3703705B1 (en) 2017-11-03 2024-05-15 DSM Nutritional Products, LLC Glucose-containing glycan preparations for use in the treatment of hyperammonaemia
EP3720967A4 (en) 2017-12-08 2021-09-08 Isothrive Inc. METHOD FOR PRODUCING MALTOSYL ISOMALTOOLIGOSACCHARIDES (MIMO)
CN108191987B (zh) * 2017-12-28 2022-01-14 山东百龙创园生物科技股份有限公司 一种抗性淀粉的制备方法
US10808269B2 (en) 2018-02-23 2020-10-20 Danisco Us Inc Synthesis of glucan comprising alpha-1,3 glycosidic linkages with phosphorylase enzymes
CN108912410A (zh) * 2018-06-24 2018-11-30 袁暾 一种含茶提取物的β-葡聚糖胶体
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
US20200113858A1 (en) * 2018-10-15 2020-04-16 Freedom Health, Llc Human dietary supplement and method for treating digestive system and immune-related disorders
CN113271794B (zh) 2018-10-25 2024-01-05 O·霍夫梅克勒 天然增甜风味组合物
EP3965776A4 (en) * 2019-05-08 2023-08-02 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use
WO2022016105A1 (en) * 2020-07-17 2022-01-20 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use
CN112553271A (zh) * 2020-12-15 2021-03-26 江南大学 一种含α-1,2糖苷键低热量糊精的制备方法
KR20240161925A (ko) 2023-05-04 2024-11-13 단국대학교 천안캠퍼스 산학협력단 류코노스톡 메젠테로이드 mksr 유래 당전이 효소로 제조된 신규 당류, 이의 용도 및 이의 제조 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2926421B2 (ja) 1988-01-29 1999-07-28 ビオヨロープ 糖代用物質の製造に有用なオリゴデキストランの酵素による合成方法および新規なオリゴデキストラン
WO2009000803A1 (en) * 2007-06-25 2008-12-31 Dsm Ip Assets B.V. Novel prebiotics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB749515A (en) * 1953-03-19 1956-05-30 Dextran Ltd Improvements in or relating to the production of dextran
JP3503238B2 (ja) 1995-01-09 2004-03-02 ソニー株式会社 適応型制御装置
KR100501584B1 (ko) 2000-02-03 2005-07-18 (주)케이비피 저분자 폴리만유로네이트의 제조방법, 혈청지질개선제로서의 이의 신규 용도 및 이를 함유하는 기능성식품 및 건강 보조 식품
DE10105305A1 (de) * 2001-02-02 2002-08-14 Nutrinova Gmbh Sorbinsäurepräparat als Futtermittelzusatz in der Nutztieraufzucht
FR2822163B3 (fr) 2001-03-16 2003-06-13 Centre Nat Rech Scient Molecules d'acides nucleiques codant une dextrane-saccharase catalysant la synthese de dextrane portant des ramifications de type alpha-1,2 osidiques
FR2822162B1 (fr) * 2001-03-16 2003-06-27 Inst Nat Sciences Appliq Molecules d'acides nucleiques codant une dextrane-saccharase calatalysant la synthese de dextrane portant des ramifications de type alpha-1,2 osidiques
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
FR2844453B1 (fr) * 2002-09-13 2006-05-19 Agronomique Inst Nat Rech Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii
CN1690085A (zh) 2004-04-30 2005-11-02 天津振和生物工程有限公司 一种水溶性多聚糖及其生产方法
FR2875406B1 (fr) * 2004-09-21 2007-01-05 Danisco Souche de lactobacillus acidophilus ayant des proprietes analgesiques au niveau du systeme gastro-intestinal
FR2897069B1 (fr) 2006-02-08 2012-06-08 Centre Nat Rech Scient Construction de nouveaux variants de l'enzyme dextrane-saccharase dsr-s par ingienerie moleculaire.
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
EP1972208A1 (en) * 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
BRPI1014800A8 (pt) 2009-05-07 2016-10-11 Tate & Lyle Ingredients France SAS "composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas"

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2926421B2 (ja) 1988-01-29 1999-07-28 ビオヨロープ 糖代用物質の製造に有用なオリゴデキストランの酵素による合成方法および新規なオリゴデキストラン
WO2009000803A1 (en) * 2007-06-25 2008-12-31 Dsm Ip Assets B.V. Novel prebiotics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Applied biochemistry and biotechnology. 1994. Vol.44 no.2 , pp.101-117 ,

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240131494A (ko) 2023-02-23 2024-09-02 유선균 웨이셀라 시바리아 ysk01 균주 및 이의 용도

Also Published As

Publication number Publication date
AU2010245761A1 (en) 2011-12-01
EP2427499A1 (en) 2012-03-14
US10167346B2 (en) 2019-01-01
AU2010245761A8 (en) 2012-06-07
CA2761150C (en) 2017-06-13
MX2011011659A (es) 2012-02-28
JP2012526145A (ja) 2012-10-25
BRPI1014800A8 (pt) 2016-10-11
KR20120027314A (ko) 2012-03-21
WO2010129839A1 (en) 2010-11-11
WO2010129839A8 (en) 2011-11-24
BRPI1014800A2 (pt) 2016-04-05
IL215936A0 (en) 2011-12-29
AU2010245761B2 (en) 2014-10-02
IL215936A (en) 2014-12-31
CN102439048B (zh) 2015-03-25
JP6077303B2 (ja) 2017-02-08
CN102439048A (zh) 2012-05-02
JP6144745B2 (ja) 2017-06-07
US20150004140A1 (en) 2015-01-01
US20170101484A1 (en) 2017-04-13
JP2016041072A (ja) 2016-03-31
US20100284972A1 (en) 2010-11-11
CA2761150A1 (en) 2010-11-11
US8816067B2 (en) 2014-08-26
US9512239B2 (en) 2016-12-06

Similar Documents

Publication Publication Date Title
KR101783383B1 (ko) 알파-(1,2)-분지형 알파-(1,6) 올리고덱스트란을 제조하기 위한 조성물 및 방법
Ibrahim Functional oligosaccharides: Chemicals structure, manufacturing, health benefits, applications and regulations
Ashwini et al. Reactive mechanism and the applications of bioactive prebiotics for human health
Baruah et al. Functional food applications of dextran from Weissella cibaria RBA12 from pummelo (Citrus maxima)
Mussatto et al. Non-digestible oligosaccharides: A review
Hidaka et al. Fructooligosaccharides enzymatic preparation and biofunctions
CN105639631A (zh) 含有非活的双歧杆菌和非消化性寡糖的营养物
US20120128634A1 (en) Use of collinsella aerofaciens for reducing bloating
CN102670662A (zh) 糖醛酸和益生菌
Gibson et al. Prebiotics
JP2010100583A (ja) 脂質代謝改善剤
Śliżewska et al. Resistant dextrins as prebiotic
CN116615116A (zh) 幼儿纤维混合物
Rabiu et al. Carbohydrates: a limit on bacterial diversity within the colon
Glibowski et al. Prebiotic and synbiotic foods
EP1887017A1 (en) Prebiotic carbohydrate
Crittenden Emerging prebiotic carbohydrates
Lee et al. Glucooligosaccharide production by Leuconostoc mesenteroides fermentation with efficient pH control, using a calcium hydroxide-sucrose solution
Jaswal et al. Prebiotic oligosaccharide production in microbial cells
WO2010117274A1 (en) Carbohydrates enhancing the production of a c5 and/or a c6 scfa
US20250101388A1 (en) Enzyme composition to reduce glucose uptake without compromising taste
Corwin Structural and Functional Properties of Enzymatically Modified Slow Digesting α-Glucans
Hughes et al. Health-functional carbohydrates: properties and enzymatic manufacture
TW202103580A (zh) 保持健康體重或減輕體重之非治療性方法
Bondia-Pons et al. Whole grains and digestive health

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150430

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160920

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170428

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160920

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170428

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20161121

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150430

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20170623

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170531

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170428

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20161121

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150430

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170925

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170926

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20200825

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20200825

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20210901

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20210901

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20220826

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20220826

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240909

Start annual number: 8

End annual number: 8